Panitumumab is currently not available.
Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Panitumumab becomes available, please fill out the form below.
*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!
Information about SaveRxCanada.to
List of countries where we can ship Panitumumab:
Latest news releases on Panitumumab:
This is a summary of the European Public Assessment Report (EPAR) for Vectibix. It explains how the Agency assessed the medicine to recommend its authorisation in the ...
Il panitumumab o ABX-EGF, nome commerciale: Vectibix, è un anticorpo monoclonale interamente umano specifico contro epidermal growth factor receptor (EGFR) o ErbB-1 ...
BackgroundPatients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti–epidermal growth factor receptor (EGFR) therapy.
Learn about Vectibix® (panitumumab), a treatment option for wild-type RAS metastatic colorectal cancer. See Prescribing Information and Boxed Warning.
Vectibix treats metastatic colorectal cancer that has progressed after treatment with other chemotherapy. Learn about side effects, interactions and indications.
Panitumumab SPECIAL PRECAUTIONS: Caution: • Severe infusion reactions, characterized by anaphylactic reaction, bronchospasm, fever, chills, and hypotension,
Learn about Vectibix® (panitumumab): an FDA-approved 1st- & 3rd-line treatment option for patients with WT RAS metastatic colorectal cancer (mCRC).
Each mL of concentrate contains 20 mg panitumumab. Each single-use vial contains either 100 mg of panitumumab in 5 mL, or 400 mg of panitumumab in 20 mL.
Our findings show that panitumumab is non-inferior to cetuximab and that these agents provide similar overall survival benefit in this population of patients. Both ...
2018 ASCO Annual Meeting. The 2018 ASCO Annual Meeting abstracts will be published on on this website on May 16th, 2018 at 5:00 PM (EDT). To view previously released ...